Considering the above, the primary objective of this study was to quantify the plasma concentration of selected regulatory molecules, such as omentin-1, NGAL and CTRP3 in the plasma of obese patients with type 2 diabetes, before introducing insulin therapy, in relation to the concentration of these molecules in plasma of obese subjects in the control group. The gene discussed is LCN2; the disease is type 2 diabetes mellitus.